Asparagine synthetase expression and phase i study with l-asparaginase encapsulated in red blood cells in patients with pancreatic adenocarcinoma

Pancreas

Volumn 44, Issue 7, 2015, Pages 1141-1147

  Bachet, Jean Baptiste ^a   Gay, Fabien ^b   Maréchal, Raphaël ^c   Galais, Marie Pierre ^d   Adenis, Antoine ^e   Salako, David ^b   Cros, Jerome ^f   Demetter, Pieter ^c   Svrcek, Magali ^g   Bardier Dupas, Armelle ^a   Emile, Jean François ^h   Hammel, Pascal ^f   Ebenezer, Christelle ⁱ   Berlier, Willy ^b   Godfrin, Yann ^b   Andre, Thierry ^g  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ERYTECH PHARMA   (France)

^c ERASME HOSPITAL   (Belgium)

^d CENTRE FRANÇOIS BACLESSE   (France)

^e CENTRE OSCAR LAMBRET   (France)

^f BEAUJON HOSPITAL   (France)

^g HÔPITAL SAINT ANTOINE   (France)

^h HÔPITAL AMBROISE PARÉ   (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

Author keywords

Asparaginase; asparagine synthetase; biomarker; CXCR4; pancreatic adenocarcinoma; treatment

Indexed keywords

ANTITHROMBIN III; ASPARAGINASE; ASPARTATE AMMONIA LIGASE; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHEMOKINE RECEPTOR CXCR4; PROTEIN KINASE LKB1; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA2; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACKACHE; BLOOD TOXICITY; BONE MARROW APLASIA; BONE MARROW BLAST FREE APLASIA; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CELL ENCAPSULATION; CONNECTIVE TISSUE DISEASE; DECREASED APPETITE; DIAGNOSTIC TEST ACCURACY STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ERYTHROCYTE; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HOT FLUSH; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; OCCLUSIVE CEREBROVASCULAR DISEASE; OPEN STUDY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATITIS; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; SEX; SIDE EFFECT; SINGLE DRUG DOSE; TRANSLATIONAL RESEARCH; VOMITING; ADENOCARCINOMA; ADVERSE EFFECTS; BIOSYNTHESIS; CLINICAL TRIAL; COHORT ANALYSIS; DRUG-INDUCED LIVER INJURY; ENZYMOLOGY; ERYTHROCYTE TRANSFUSION; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; OUTCOME ASSESSMENT; PANCREATIC NEOPLASMS; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA;

ADENOCARCINOMA; ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTINEOPLASTIC AGENTS; ASPARAGINASE; COHORT STUDIES; DRUG HYPERSENSITIVITY; DRUG-INDUCED LIVER INJURY; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84942061159     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000394     Document Type: Article

References (34)

1. Richards S, Burrett J, Hann I, et al. Improved survival with early intensification: combined results from the Medical Research Council childhood ALL randomised trials, UKALL X and UKALL XI. Medical Research Council Working Party on Childhood Leukaemia. Leukemia. 1998;12:1031-1036.
2. Jones B, Holland JF, Glidewell O, et al. Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia. Med Pediatr Oncol. 1977;3:387-400.
3. Gökbuget N. How I treat older patients with ALL. Blood. 2013;122: 1366-1375.
4. Domenech C, Thomas X, Chabaud S, et al. L-Asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol. 2011;153:58-65.
5. Lorenzi PL, Reinhold WC, Rudelius M, et al. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther. 2006;5:2613-2623.
6. Lorenzi PL, Weinstein JN. Asparagine synthetase: a new potential biomarker in ovarian cancer. Drug News Perspect. 2009;22:61-64.
7. Dufour E, Gay F, Aguera K, et al. Pancreatic tumor sensitivity to plasma L-asparagine starvation. Pancreas. 2012;41:940-948.
8. Zhang B, Dong LW, Tan YX, et al. Asparagine synthetaseisan independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma. Br J Cancer. 2013;109:14-23.
9. Carpelan-HolmströmM, Nordling S, Pukkala E, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut. 2005;54:385-387.
10. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CACancer J Clin. 2009;59:225-249.
11. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15: 2403-2413.
12. Conroy T, Desseigne F, Ychou M, et al. Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825.
13. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369: 1691-1703.
14. Yunis AA, Arimura GK, Russin DJ. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer. 1977;19:128-135.
15. Wu MC, Arimura GK, Yunis AA. Mechanism of sensitivity of cultured pancreatic carcinoma to asparaginase. Int J Cancer. 1978;22:728-733.
16. Sapra P, Zhang Z, Longley C, et al. In vitro and in vivo evaluation of pegaspargase for the treatment of solid tumors and lymphomas. Eur J Cancer. 2006;4(abstract 160):51.
17. Bachet JB, Maréchal R, Demetter P, et al. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy inresected pancreatic adenocarcinoma. Ann Oncol. 2012;23:2327-2335.
18. Bachet JB, Maréchal R, Demetter P, et al. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. Eur J Cancer. 2013;49:2643-2653.
19. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol. 2005;2:416-422.
20. O'Quigley J, Zohar S. Experimental designs for phase I and phase I/II dose-finding studies. Br J Cancer. 2006;94:609-613.
21. Su N, Pan YX, Zhou M, et al. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines. Pediatr Blood Cancer. 2008;50: 274-279.
22. Milman HA, Cooney DA. The distribution of L-asparagine synthetase in the principal organs of several mammalian and avian species. Biochem J. 1974;142:27-35.
23. Aslanian AM, Fletcher BS, Kilberg MS. Asparagine synthetase expression alone is sufficient to induce L-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem J. 2001;357(Pt 1):321-328.
24. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351:533-542.
25. Appel IM, den Boer ML, Meijerink JP, et al. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood. 2006;107:4244-4249.
26. Poznansky MJ, Shandling M, Salkie MA, et al. Advantages in the use of L-asparaginase-albumin polymer as an antitumor agent. Cancer Res. 1982;42:1020-1025.
27. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16:2927-2931.
28. Patrikainen L, Porvari K, Kurkela R, et al. Expression profiling of PC3 cell line variants and comparison of MIC-1 transcript levels in benign and malignant prostate. Eur J Clin Invest. 2007;37:126-133.
29. Ameri K, Luong R, Zhang H, et al. Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. Br J Cancer. 2010;102:561-569.
30. Cui H, Darmanin S, Natsuisaka M, et al. Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin. Cancer Res. 2007;67:3345-3355.
31. Lessner HE, Valenstein S, Kaplan R, et al. Phase II study of L-asparaginase in the treatment of pancreatic carcinoma. Cancer Treat Rep. 1980;64: 1359-1361.
32. Hays JL, Kim G, Walker A, et al. A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: early closure for safety. Mol Clin Oncol. 2013;1:565-569.
33. Narta UK, Kanwar SS, Azmi W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol. 2007;61:208-221.
34. Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52:2237-2253.